Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: "uveal melanoma" Condition: Melanoma Clear all
Completed Phase 1Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

NCT00005815
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

A Study of PLX2853 in Advanced Malignancies.

NCT03297424
View directory record Official record
Conditions
Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancies, Solid Tumor, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Interventions
PLX2853
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

NCT00661622
View directory record Official record
Conditions
Uveal Melanoma, Liver Metastases
Interventions
GM-CSF, Embolization
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 14, 2026, 7:10 AM EDT
Recruiting Phase 1 Interventional

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT04119024
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
Anusha Kalbasi
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma

NCT00062933
View directory record Official record
Conditions
Melanoma
Interventions
Laparotomy
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 14, 2026, 7:10 AM EDT
Active, not recruiting Phase 2 Interventional

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

NCT03467516
View directory record Official record
Conditions
Uveal Neoplasms, Melanoma, Uveal
Interventions
Tumor Infiltrating Lymphocytes (TIL)
Biological
Lead sponsor
Udai Kammula
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Not yet recruiting Phase 2 Interventional

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

NCT07803562
View directory record Official record
Conditions
Uveal Melanoma, Metastatic
Interventions
Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 7:10 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

NCT01814046
View directory record Official record
Conditions
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00680225
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Ranibizumab injection and TTT - ICG based
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00058279
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
aldesleukin, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 14, 2026, 7:10 AM EDT
Active, not recruiting Phase 2 Interventional

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT04728633
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Interventions
Carmustine, Ethiodized Oil, Transarterial Chemoembolization, Medical Device Usage and Evaluation
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT00765921
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398
View directory record Official record
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

NCT00003339
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

NCT00750399
View directory record Official record
Conditions
Radiation Retinopathy, Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
The New York Eye Cancer Center
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

NCT02570308
View directory record Official record
Conditions
Uveal Melanoma
Interventions
IMCgp100
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

NCT01961115
View directory record Official record
Conditions
Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Skin Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Skin Melanoma, Stage IIIC Uveal Melanoma, Stage IV Skin Melanoma, Stage IV Uveal Melanoma
Interventions
Epacadostat, MELITAC 12.1 Peptide Vaccine
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 14, 2026, 7:10 AM EDT
Recruiting Phase 3 Interventional

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Active, not recruiting Phase 2 Interventional

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

NCT05524935
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

NCT05004025
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Novocure Optune, Opdivo, Yervoy
Device · Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 14, 2026, 7:10 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Recruiting Phase 2 Interventional

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

NCT06121180
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
ZIV-Aflibercept, Cemiplimab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 14, 2026, 7:10 AM EDT
Completed No phase listed Observational

New Biopsy Technique for Uveal Melanoma

NCT01924923
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Not listed
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 14, 2026, 7:10 AM EDT